Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer

Article Abstract:

Pretreatment with a cloned version of thrombopoietin appears to be successful in increasing blood platelet production among patients at risk for low platelet counts. Thrombopoietin treatment was given to 12 patients with cancer three weeks before chemotherapy. Platelet counts increased by 61% to 213% depending on the amount of thrombopoietin given. Platelet characteristics were normal. The median day for maximum platelet counts was 12 days after the injection. The number of bone marrow cells that produce platelets also increased. There were no significant side effects reported with thrombopoietin treatment.

---

Thrombopoietin: platelets on demand?

Article Abstract:

Studies have shown genetically replicated thrombopoietin therapy to be significantly effective in increasing platelet counts among selected at-risk patients. Platelet counts increased two to six times baseline levels among cancer patients given thrombopoietin before chemotherapy. These patients had no history of heart disease. This therapy may prove useful before or after other bone marrow suppressing therapies or as a normal platelet transfusion additive. There have been few reported side effects with this therapy since thrombopoietin has no other known function than to regulate platelet production.

Editorial

---

Recombinant Human Thrombopoietin Attenuates Carboplatin-Induced Severe Thrombocytopenia and the Need for Platelet Transfusions in Patients with Gynecologic Cancer

Article Abstract:

Recombinant human thrombopoietin (rhTPO) may prevent thrombocytopenia in cancer patients if they receive it when they receive chemotherapy. Thrombocytopenia is a decrease in blood platelets, which participate in blood clotting. Thrombopoietin is the hormone that stimulates the production of platelets. In a study of 29 women with cancer, rhTPO prevented platelet levels from dropping too low and reduced the need for a platelet transfusion.

Prevention, Complications and side effects, Chemotherapy

Similar abstracts:

• Abstracts: A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease
• Abstracts: Evolution of risk behaviors over 2 years among a cohort of urban African American adolescents. A Randomized, Controlled Effectiveness Trial of an AIDS Prevention Program for Low-Income African-American Youths
• Abstracts: Mutations in the sarcoglycan genes in patients with myopathy. The muscular dystrophies - clarity or chaos?
• Abstracts: Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. A comparison of omeprazole and placebo for bleeding peptic ulcer
• Abstracts: AMA urges nation to broaden public health perspective. Dr. Satcher urges different kind of response: collaborations needed to improve U.S. health

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.